Margarida Maia, PhD,  science writer—

SUDO-550, an oral TYK2 inhibitor being developed by Sudo Biosciences, was found to be safe, well-tolerated, and to fully reach the brain in a first-in-human clinical trial involving healthy volunteers, according to clinical trial results. The Phase 1 clinical trial, which began dosing late last year, also showed…

Enrollment is complete for the randomized part of ENHANCE, a large clinical trial testing a new dosing schedule for Briumvi (ublituximab-xiiy) in adults with relapsing forms of multiple sclerosis (MS), developer TG Therapeutics announced. This part of the Phase 3b ENHANCE study (NCT05877963) is specifically testing whether…

Obexelimab, a therapy Zenas Biopharma is developing for a range of autoimmune diseases, almost completely prevented the formation of new inflammatory lesions in adults with relapsing forms of multiple sclerosis (MS) in the first three months of a clinical trial. That’s according to data from the first part…

The first patient has been dosed in a Phase 1 clinical trial of Autolus Therapeutics‘ experimental CAR T-cell therapy, obecabtagene autoleucel (obe-cel), in people with progressive forms of multiple sclerosis (MS) who have failed to respond to existing treatments. Dosing took place at University College London Hospitals NHS…

A gene on the X chromosome that is more active in women than men appears to drive inflammation in the brain, helping to explain why women are more likely to develop neurological diseases such as multiple sclerosis (MS) and Alzheimer’s disease, according to a study out of the…

The U.S. Food and Drug Administration (FDA) has given Tr1x the green light to launch a first-in-human clinical trial of TRX319, a cell therapy candidate designed to restore immune balance in people with progressive forms of multiple sclerosis (MS). With FDA clearance now granted for its investigational new…

An international research team has secured nearly $800,000 (about CA$1.1 million) to advance a potential regenerative therapy for multiple sclerosis (MS) toward clinical testing. While existing treatments can slow disease progression, none can repair the nerve damage that has already occurred. This new project aims to change that by…

The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to Hope Biosciences‘ adipose-derived mesenchymal stem cells (HB-adMSCs) to treat relapsing-remitting multiple sclerosis (RRMS). RMAT status is given to therapies with compelling proof that they may substantially improve patient outcomes compared with existing…

The International Progressive MS Alliance has introduced the MS Clinical and Imaging Data Resource, or CIDR, to accelerate the search for effective treatments for progressive forms of multiple sclerosis (MS) where options are limited. The resource was built in partnership with McGill University in Canada, as well as…

For children and adolescents with multiple sclerosis (MS), receiving treatment with Copaxone (glatiramer acetate) or its generic formulations may reduce relapses by nearly threefold compared with Avonex (interferon beta-1a), according to data from a clinical trial. However, nearly half of patients on Copaxone and one-third of those…

People genetically prone to a higher body mass index (BMI) are also more likely to develop multiple sclerosis (MS), a study finds. The findings confirm an association between being overweight or obese and a higher likelihood of developing MS, and suggest that lifestyle changes to maintain a healthy weight…

People who develop multiple sclerosis (MS) begin using healthcare services more frequently up to 15 years before their first MS symptoms appear, a study from the University of British Columbia (UBC) suggests. The findings add to evidence that early signs of MS may go unnoticed for many years.

Lucid-MS, an oral small-molecule being developed by Quantum Biopharma for treating multiple sclerosis (MS), was found to be safe and well tolerated in healthy adult volunteers when given daily in a clinical study, according to the company’s latest CSR, or clinical study report. An earlier Phase 1…

Neurofilament light chain (NfL) — a protein that gets released when nerve cells are damaged — is found at high levels in the blood and cerebrospinal fluid (CSF) of people with multiple sclerosis (MS), suggesting its potential as a biomarker of the disease, a study has found. CSF is…

In progressive forms of multiple sclerosis (MS), treatment with estrogen hormones such as estradiol may help reduce inflammation and nerve damage — especially among patients for whom the disease may be triggered or worsened by viral infections — a mouse study has found. U.S. researchers investigating the impact of sex…

People with multiple sclerosis (MS) are significantly more likely to visit an emergency department if they have other health problems, aren’t on disease-modifying treatments (DMTs), or have public or no insurance, according to a study at Massachusetts General Hospital in Boston. “Although ED [emergency department] visits for MS…

Regular exercise that follows established guidelines for physical activity in multiple sclerosis (MS) leads to clinically meaningful gains in depression and supports its use as a nonpharmacological treatment for people with MS, a meta-analysis of 12 studies suggests. The meta-analysis, “Effects of meeting exercise guidelines on depression and…

People with multiple sclerosis (MS) visited doctors, were admitted to the hospital, and used emergency care more often than other people more than two decades before their diagnosis, a large study finds. The use of these services peaked in the year before a diagnosis, but visits to a primary…

The rates of people with multiple sclerosis (MS) who advance from a relapsing disease course to a secondary progressive one have decreased significantly in the past decades, a 30-year study in Italy shows. While the greater availability and earlier use of disease-modifying therapies (DMTs) have played a role,…

Following the MIND diet plan, rich in leafy greens, whole grains, legumes, nuts, berries, and lean meats, may help strengthen the body’s antioxidant defenses in people with multiple sclerosis (MS), a study found. The Mediterranean-DASH Diet Intervention for Neurodegenerative Delay (MIND) diet combines the Mediterranean diet, which emphasizes those…

In healthy adults, a single low dose of Immutep’s immunosuppressive candidate IMP761 continues to be safe and appears to reduce the activity of T-cells — immune cells that become overactive in multiple sclerosis (MS) and other autoimmune diseases. This is according to data from an ongoing Phase…

People who develop multiple sclerosis (MS) at a younger age tend to consistently have better physical health but worse mental health than those diagnosed later, a study found. While physical health declined in the long term for all age groups, and mental health increased, the differences between groups were…

Ambio Life Sciences has launched a clinical program to test ibogaine — an experimental, naturally occurring psychedelic — for neurodegenerative conditions such as multiple sclerosis (MS). The program aims to offer therapeutic support in a safe, medically supervised setting. Now open to the public following a soft launch…

Enrollment is now complete in the twin Phase 3 clinical trials testing Immunic Therapeutics‘ oral small molecule vidofludimus calcium in adults with relapsing forms of multiple sclerosis (MS). ENSURE-1 (NCT05134441) has enrolled 1,121 patients and ENSURE-2 (NCT05201638) has enrolled 1,100 patients at more than 100…

Body mass index (BMI), a measure commonly used measure of body fat based on a person’s height and weight, does not seem to affect responses to stem cell transplant in people with multiple sclerosis (MS), a study found. While the efficacy of an autologous transplant — one that…

Almost two years of treatment with fenebrutinib — an investigational oral tablet for multiple sclerosis (MS) — helped patients with relapsing forms of the disease remain nearly free of relapses and disability progression. That’s according to new data from the open-label extension of FENopta (NCT05119569), a Phase…

While subtle symptoms of multiple sclerosis (MS) — like muscle weakness, fatigue, and numbness or unusual sensations — are often overlooked in individuals with minimal disability, more detailed clinical tools can help detect these early signs, according to a new study from Italy. Moreover, such tools — including wearable…

Half of multiple sclerosis (MS) patients in the U.K. who work have compromised their health by staying in jobs that didn’t fully support their MS needs, and nearly a third are in roles below their skill levels. That’s according to “No compromises: supporting people with MS to thrive…

A 10-week program that combines cognitive behavioral therapy — a technique focused on understanding the connection between thoughts, feelings, and behaviors — with cognitive training to improve memory, attention, and problem-solving skills may enhance memory, boost vitality, and help people with multiple sclerosis (MS) develop effective coping strategies. “These…

Stem cells from donated placentas appear safe and may help reduce symptoms of secondary progressive multiple sclerosis (MS), according to a small, open-label Phase 1 clinical trial involving five patients. “Our results suggest possible neuroprotective effects” from these stem cells, researchers wrote in “Cell therapy with placenta-derived mesenchymal…